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More than 80% of human tumours are carcinomas of epithelial
origin, and direct or metastatic spread to pleural and mesothelial
spaces is common. It is sometimes difficult to detect epithelial
cancer cells in the resultant effusions by routine cytopathological
examination because of their small numbers. Currently, the sensi-
tivity of cytopathological examination for the detection of tumour
cells is in the range of one tumour cell per 103—105 of total cell
number (Pelkey et al, 1996). In addition, the cytological distinc-
tion of reactive mesothelial cells from malignant cells may be
difficult (Tickman et al, 1990).
Recently, polymerase chain reaction (PCR)-based methodolo-
gies have been introduced as sensitive tests for the detection of
rare cancer cells in peripheral blood (Datta et al, 1994), lymph
nodes (Schoenfeld et al, 1994), bone marrow aspirates (Fields et
al, 1996) and other clinical specimens (Tr￿mper et al, 1994). PCR-
based methods fall into three categories: (a) methods to detect
cancer-specific products or genes such as mutated K-ras genes,
which reveal the presence of circulating pancreatic cancer cells
(Nomoto et al, 1996); (b) methods to detect expression of genes
specific for the tissue of origin of the tumour cell, such as prostate-
specific antigen, which indicates the presence of circulating or
micrometastatic prostate carcinoma cells (Katz et al, 1994); and
(c) methods to detect expression of epithelial cell-specific genes
such as cytokeratin 19 (K19), which is indicative of circulating or
micrometastatic carcinoma cells (Datta et al, 1994; Schoenfeld et
al, 1994; Fields et al, 1996; Noguchi et al, 1996a, 1996b). The last
approach is not restricted to one or a few tumour types, and is
useful for the detection of tumour cells from many, as well as
unknown, sites of origin in fluids or tissues. Recent reports indi-
cate that epithelial glycoprotein 2 (EGP-2) is expressed on the
surface of most epithelial cells and tumours (Simon et al, 1990;
de Leji et al, 1994), but not by mesothelial cells (Latza et al, 1990).
Although several different nomenclatures have been used for the
gene and its protein product, we use the term EGP-2 as proposed
by de Leij et al (1994). Several antibodies to EGP-2 cell-surface
protein have been described, but the most widely utilized is the
monoclonal antibody Ber-EP4 (Latza et al, 1990). Ber-EP4
immunostaining has been used for the identification of carcinoma-
tous effusions (Sheibani et al, 1991; de Angelis et al, 1992;
Illingworth et al, 1994; Maguire et al, 1994).
Sensitive methods for the gene expression of cancer cells
usually rely on reverse transcriptase PCR (RT-PCR) to detect RNA
transcripts. Although many reports have documented the extreme
sensitivity of RT-PCR methods for the detection of low tumour
burden, false-positive results may render them as unsuitable for
screening approaches. False-positive results may be due to: (a)
lineage infidelity (i.e. expression of rare epithelial cell transcripts
by occasional non-epithelial cells); (b) detection of genomic
sequences in contaminating DNA; and (c) detection of transcripts
of other genes. Whereas careful primer design and testing may
overcome some of these problems, ectopic expression (lineage
infidelity) remains a major source of false-positive results,
especially when RNA from large numbers of test cells is utilized.
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Summary We developed a sensitive and specific method for the detection of epithelial cancer cells in effusions with a two-stage molecular-
based assay which combined enrichment for cancer cells by immunomagnetic bead selection and reverse transcriptase polymerase chain
reaction (RT-PCR) detection of epithelial glycoprotein 2 (EGP-2) RNA. Preliminary experiments indicated that immunobead selection was
essential to avoid occasional false-positive RT-PCR results, and this method detected ten breast cancer cells electively added to 107
cytologically negative effusion cells. We studied 110 cases of pleural (n = 68) and peritoneal (n = 42) effusions (30 from patients with known
carcinoma and 80 from those without known carcinoma), and the results were compared with cytological findings. Of 18 effusions that were
cytologically positive or suspicious for malignant cells, 17 (94%) were positive for EGP-2 RNA (the one negative sample was from a patient
who recently received combination chemotherapy). Of 92 cytologically negative samples, 11 (12%) were positive for EGP-2, including six
patients with a history of previous or current carcinoma. Our method appears to be highly specific and increases the sensitivity of detection of
malignant cells; it may be a useful adjunct to routine cytopathological examination.
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A recent report demonstrated expression of seven out of eight
epithelial cell and tumour-linked genes (including EGP-2) in bone
marrow samples from control subjects when 106 test cells were
utilized (Zippelius et al, 1997). Although the mechanism of
lineage infidelity is unknown, it may represent occasional loss of
transcriptional control.
In an effort to design a specific and sensitive test for the detec-
tion of epithelial cancer cells in effusion fluids, we developed a
two-stage RT-PCR-based assay. The first step is selective enhance-
ment of the tumour cell population using immunomagnetic beads
and a monoclonal antibody to an epithelial cell-specific surface
protein. Because non-epithelial cells are absent or present in low
numbers after immunobead selection, immunobead RT-PCR-
based detection of epithelial cell-related transcripts renders the test
highly specific. In this report, we describe the application of this
test to the detection of carcinoma cells in effusion fluids.
MATERIALS AND METHODS
Our approach to the detection of micrometastases has been
published in abstract form (Sakaguchi et al, 1997).
Patient characteristics
The clinical diagnoses of the 110 patients studied are summarized
in Table 1. Sixty-eight pleural and 42 peritoneal effusions were
obtained between September 1996 and April 1997 from patients
attending Parkland Memorial Hospital and Veteran￿s
Administration Medical Center Hospital in Dallas, TX, USA. Of
these, 30 were from patients with prior or current epithelial
cancers, including 22 pleural effusions and eight ascites.
Specimens were kept refrigerated and released for laboratory
studies only when cytological examination was complete (average
of 2 days after removal from the patient, range 1—7 days).
Specimens were collected after obtaining informed consent.
Appropriate Institutional Review Board permission was obtained
for these studies.
Cell lines
Most of the tumour and B-lymphoblastoid cell lines were initiated,
maintained and characterized by us as published previously (Oie et
al, 1996). Some lines were obtained from the American Type
Culture Collection, Rockville, MD, USA.
Flow cytometry
EGP-2 cell-surface protein expression was determined by disag-
gregating cultured cells, and incubating the resultant single-cell
suspension (106 cells) with 10 mg of fluorescein isothiocyanate
(FITC)-conjugated Ber-EP4 monoclonal antibody (Dako,
Denmark). Non-specific binding was determined by use of an
isotype control. Immunoreactivity was determined by use of a
FACScan flow cytometer (Becton Dickinson Immunocytometry
Systems, San Jose, CA, USA).
Preparation of cells from effusions
Fifty millilitres of the effusion was centrifuged at 500 g for 10 min
at room temperature. Pellets were washed once and resuspended in
phosphate-buffered saline (PBS) containing 0.01% bovine serum
albumin and a cell count was obtained. Although cytological
examination indicated the persistence of tumour cells in refriger-
ated malignant effusions for several days, we were concerned
about the possibility that RNA expression was down-regulated or
absent in specimens refrigerated for lengthy periods. Therefore,
for specimens reaching the laboratory more than 48 h after
removal from the patient, we resuspended the cell pellet in ACL4
medium (Gazdar et al, 1986) plus 5% fetal bovine serum and incu-
bated them in a Petri dish at 37°C in 5% carbon dioxide. After
overnight incubation, the cells were harvested with a cell scraper,
repelleted and handled as described above. Of the 110 clinical
samples tested, 19 were cultured overnight before cell harvest.
Selection of tumour cells by immunomagnetic beads
Cells (106—107) suspended in 4 ml of PBS were incubated with
1.25 ng of Ber-EP4 monoclonal antibody at 4°C for 1 h with
gentle rotation. The cells were then washed twice with PBS and
centrifuged at 400 g for 5 min and resuspended in 1.8 ml of PBS in
2 ml microcentrifugation tubes. Immunobeads (Dynabeads,
Dynal, Oslo, Norway) coated with sheep anti-mouse IgG1 (Fc)
were added at a cell/bead ratio of 5:1 and incubated at 4°C for 1 h
with gentle rotation. Cells specifically bound to immunobeads
were selected by three cycles of washing with PBS and magnetic
attraction (as per manufacturer￿s instructions and equipment).
After initiation of these studies, immunobeads directly labelled
with BER-EP4 were available commercially (Dynabeads anti-
epithelial cell, Dynal). After confirming that both the indirect and
Table 1 Clinical diagnoses of patient population (n = 110)
Patients with known carcinoma Patients without known carcinoma
(cytologically positivea/total) (cytologically positive/total)
Lung carcinoma 5/10 Chronic hepatic disease 0/13
Breast carcinoma 3/7 Heart failure 0/5
Ovarian carcinoma 3/4 Lymphoma 0/5
Colorectal carcinoma 1/3 Pneumonia 0/2
Prostatic carcinoma 0/2 Renal failure 0/2
Laryngeal carcinoma 0/1 Gastric ulcer 0/2
Renal cell carcinoma 0/1 Benign ovarian tumour 0/2
Skin carcinomas (multiple) 0/1 Pancreatitis 0/1
Pancreatic carcinoma 0/1 AIDS 0/1
Effusion of unknown cause 6/47
aThese figures include two cases cytologically diagnosed as ‘suspicious for malignant cells’. Of the 110 samples received for testing, 68 were pleural effusions
(11 of which were cytologically positive and two ‘suspicious’), whereas 42 were ascites (five of which were cytologically positive).418 M Sakaguchi et al
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direct methods gave the same results with clinical specimens (data
not shown), we substituted the directly labelled immunobeads for
the last six samples.
RNA extraction
Total RNA was isolated from the magnetically selected cells by
using the Microscale RNA Extraction Kit (Clontech Laboratories,
Palo Alto, CA, USA) following the manufacturer￿s instructions.
After pelleting, RNA was dissolved in 20 ml of diethylpyrocar-
bonate-treated water and used for reverse transcription without
further dilutions.
Reverse transcription
Because the amount of RNA from small numbers of magnetically
selected cells was too low to quantitate, the whole aliquot of RNA
solution was used to synthesize cDNA. One microgram of 5¢-
pd(T)12—18 —3¢ primer (Pharmacia Biotech, Piscataway, NJ, USA)
was added and the samples were incubated at 80°C for 10 min, and
subsequently chilled on ice. The denatured RNA was mixed with a
reaction mixture containing 500 U of Superscript II reverse tran-
scriptase (Life Technologies, Gaithersburg, MD, USA), 10 ml of 5
´ first-strand reaction buffer (Life Technologies), 5 ml of 0.1 M
DTT (Life Technologies), 500 mM of dNTP mixture, 3 ml of Prime
RNAAse inhibitor (5 Prime ® 3 Prime, Boulder, CO, USA) in the
50 ml of final volume. The reaction was performed at 42°C for 1 h
and then incubated at 95°C for 10 min to inactivate the enzyme.
PCR
For EGP-2 PCR, 20 ml of reaction mixture containing 2.5 ml of 10
´ PCR buffer (Life Technologies), 100 mM of dNTP mixture, 10
pmol of both sense and antisense primers, 1.5 mM of magnesium
chloride and 2.5 U of Taq polymerase (Life Technologies) was
added to 5 ml of the reverse-transcribed product. The sequences of
the primers for EGP-2 were as follows: sense: 5¢-GAACAAT-
GATGGGCTTTATGA-3¢; antisense: 5¢-TGAGAATTCAGGT-
GCTTTTT-3¢.
The resultant PCR product was 515 bases. Because the primer
sequences were obtained from the published cDNA sequence
Table 2 EGP-2 cell-surface protein expression by cell lines as determined
by flow cytometric analysis
Cell line No. positive/ Mean
no. tested fluorescence
(%) channela
B-lymphoblastoid 0/10 (0) (< 5)
Breast carcinoma 9/10 (90) 272
Colon carcinoma 12/13 (92) 570
Non-small-cell lung carcinoma 6/10 (60) 348
Small-cell lung carcinoma 8/9 (89) 230
All carcinomas 35/42 (83) 382
aMean value of positive samples. A sample was considered positive if the
mean fluorescence of the test sample was five or more channels greater than
the isotype control.
AB
C
Figure 1 Immunobead selection of carcinoma cells. Cells in a cytologically positive pleural effusion were incubated with or without Ber-EP4 followed by
magnetic selection. With the use of antibody (A and B), cancer cells were selected, whereas no cells were visible when antibody was excluded (C).
(magnification A, ´ 120; B and C, ´ 30)Molecular assay for malignant effusions 419
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(Simon et al, 1990), the exon(s) amplified are unknown. At the
beginning of our study, we tested whether the genomic DNA could
be amplified with these primers. Genomic DNA extracted from
breast cancer cell lines revealed no amplification of this molecular
weight. Moreover, exclusion of the reverse-transcription step
resulted in failure to obtain a PCR product, thus excluding the
possibility that we were amplifying genomic DNA.
After denaturation by heating the samples at 94°C for 4 min,
PCR amplification was performed under the following conditions:
the initial six cycles were performed with a touch-down
programme at 94°C (45 s), from 67°C to 62°C with decreasing
1°C of annealing temperature per cycle (90 s), and 72°C (2 min),
followed by 30 cycles of amplification at 94°C (45 s), 61°C
(1 min) and 72°C (1 min) with the final extension step for 7 min at
72°C. PCR products were electrophoresed on 2% agarose gel
containing ethidium bromide. The sequences of primers for K19
and the PCR conditions were as described by Noguchi et al
(1996a).
RESULTS
Expression of EGP-2 RNA and protein by cultured
carcinoma cells
Using a large panel (n = 85) of cultured epithelial tumour cell
lines, EGP-2 was expressed in 100% of all small-cell and non-
small-cell lung (n = 40), breast (n = 20), colorectal (n = 21) and
miscellaneous (n = 4) cancers when 10 ng of RNA was used. Ten
B-lymphoblastoid lines were negative for expression when 10 ng
of RNA were utilized, but positive for expression when 1 mg of
RNA was used.
By flow cytometric analysis, using antibody Ber-EP4, 35 (83%)
of 42 carcinoma cell lines expressed EGP-2 cell-surface protein,
whereas all ten B-lymphoblastoid cell lines were negative (Table
2). We arbitrarily designated cell lines whose mean fluorescence
channel was greater than 100 as high expressors, and those whose
mean channel number was less than 100 as low expressors. Of the
35 positive cell lines, 28 (80%) were high expressors. High- and
low-expressor breast carcinoma cell lines MCF7 (mean fluores-
cence channel 475) and HCC1187 (mean fluorescence channel 61)
were selected for further studies (see below). Both cell lines
expressed K19 and EGP-2 when concentrations of 10 and 100 pg,
respectively, of total RNA were tested (data not shown).
Immunobeads enrichment of tumour cells
To confirm that immunobead selection was enriching for tumour
cells, known cytologically positive effusion samples were incu-
bated with or without Ber-EP4 antibody followed by magnetic
selection, and stained with Papanicolau. Cells with malignant
cytological features were selected from the antibody-coated
samples, whereas no cells were detected in the samples incubated
without Ber-EP4 (Figure 1).
Detection of K19 expression
To determine the minimum RNA concentration detected by our
RT-PCR conditions, total RNA extracted from breast cancer cell
line, MCF-7, was serially diluted ten fold and amplified by RT-
PCR as described above. RT-PCR for K19 generated a 460-bp
amplicon and the band was detected when concentrations equal or
greater than 10 pg of total RNA extracted from cultured MCF-7
breast cancer cells were used. Initial RT-PCR detection experi-
ments were performed using pelleted cells (1 ´ 107) from seven
effusions (five cytologically negative from patients not known to
have cancer, and two cytologically positive samples from known
cancer patients). K19 expression was present in all seven samples
before selection, and in the two cytologically positive and three
of the five cytologically negative samples after immunobead
selection (Figure 2).
Detection of EGP-2 expression
RT-PCR for EGP-2 generated a 515-bp amplicon and the band was
detected when concentrations equal or greater than 100 pg of total
RNA extracted from MCF-7 cells were utilized for RT-PCR.
Without immunobead selection, all five cytologically negative
samples were positive for EGP-2 expression, although they all
were negative after immunobead selection, EGP-2 expression was
present in the two cytologically positive samples before and after
immunobead selection (Figure 2).
To determine the sensitivity of tumour cell detection, we added
various concentrations of low-EGP-2-expressing HCC1187 breast
cancer cells into cytologically negative effusion samples. After
immunobead selection, EGP-2 mRNA expression could be
detected at a sensitivity of one tumour cell per 106 effusion cells
(Figure 3).
Figure 2 Comparison of K19 and EGP-2 RT-PCR with or without
immunobead selection. Both of the RT-PCR products with (+) and without (–)
immunobead selection of two cytologically positive samples (sample nos. 1
and 2) and negative samples (sample nos. 3–7) were electrophoresed in
parallel
23 7 5 4 16
–– – – – –– ++ + + + ++
K19
EGP-2
515 bp
460 bp
Table 3 Comparison between cytopathological examination and RT-PCR
for K19 and EGP-2 for the detection of carcinoma cells in effusions
Cytological RT-PCR results
diagnosis (n)
K19 positive EGP-2 positive
(%) (%)
Patients Positive (11) 11 (100) 10 (91)
with known Suspicious (2) 2 (100) 2 (100)
carcinoma (n = 30) Negative (17) 13 (76) 6 (35)
Patients without known Positive (5) 5 (100) 5 (100)
carcinoma (n = 80) Negative (75) 40 (53) 5a (7)
Total subjects Positive (16) 16 (100) 15 (94)
analysed (n = 110) Suspicious (2) 2 (100) 2 (100)
Negative (92) 53 (58) 11 (12)
aOne subject diagnosed with metastatic carcinoma of unknown origin 1
month later.420 M Sakaguchi et al
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K19 and EGP-2 expression in clinical samples
Based on the above-mentioned results, we tested 110 clinical
effusion samples for K19 and EGP-2 expression after
immunobead selection, and the results were compared with the
cytological diagnoses (Table 3). Of these 110 samples, 68 were
pleural effusions (11 of which were cytologically positive and two
￿suspicious￿), whereas 42 were ascites (five of which were cyto-
logically positive). Laboratory staff were blinded as to cytological
results until after completion of the assays.
There were 18 cases which were cytologically positive (n = 16)
or suspicious (n = 2) for the presence of carcinoma cells, and 92
cytologically negative cases. All 18 cytologically positive or
suspicious cases were positive for K19 expression, whereas 53
(58%) of the cytologically negative cases were also positive.
EGP-2 expression was present in 17 (94%) of 18 cytologically
positive or suspicious cases, and in 11 (12%) of cytologically
negative cases. The single cytologically positive/EGP-2 expres-
sion negative sample was from a patient with breast cancer who
had received multiagent chemotherapy within the previous 3
weeks and the cellularity of the effusion was low. Of the 11 cyto-
logically negative/EGP-2-positive cases, six patients had a history
of prior or present carcinoma, three of whom currently had exten-
sive metastatic disease. The results of follow-up of the remaining
five cytologically negative/EGP-2-positive cases were as follows:
case 1 was diagnosed with carcinoma of unknown site 1 month
later; case 2 died 1 month later with hepatic failure of unknown
cause; case 3 was diagnosed with non-Hodgkin￿s lymphoma 14
months later; case 4 is alive without evidence of cancer 10 months
later; and case 5 was lost to follow-up. Our interpretation of these
five outcomes is that the results of the molecular assay were prob-
ably accurate in case 1, and could not be interpreted with certainty
in the other cases.
DISCUSSION
We developed a PCR-based assay for expression of the epithelial-
associated gene products K19 and EGP-2 for the detection of
epithelial cancer cells in effusions. Because preliminary experi-
ments demonstrated that both K19 and EGP-2 were frequently
expressed in cell pellets from both cytologically positive and nega-
tive specimens, we utilized a preliminary step using immunobead
selection to capture carcinoma cells expressing EGP-2 cell-surface
protein. Experiments with cell lines indicated that most epithelial
carcinoma cell lines expressed EGP-2 cell-surface protein, whereas
lymphoblastoid cell lines lacked protein expression. At high RNA
concentrations (1 mg), both carcinoma and lymphoblastoid lines
expressed EGP-2 RNA; however, at lower concentrations (10 ng)
expression was absent in lymphoblastoid lines. More recently,
without immunobead selection, in terms of EGP-2 expression, it
has been also demonstrated that bone marrow aspirates (Helfrich et
al, 1997) or peripheral blood cells (de Graaf et al, 1997) could yield
false-positive reactions by sensitive RT-PCR methods even with
samples obtained from normal volunteers. By flow cytometric
examination, 83% of epithelial cell lines expressed EGP-2
cell-surface protein, usually at relatively high levels, whereas
B-lymphoblastoid lines were uniformly negative. We interpret
these results to indicate that lymphoblastoid cells may express
EGP-2 ￿illegitimately￿ when high concentrations of RNA are used,
and that some form of enrichment is required for the detection of
epithelial cells when present in low concentrations in marrow,
blood or effusions.
Cytokeratins are one of the most widely utilized molecular
markers for the detection of epithelial cancer cells in blood, bone
marrow aspirates and lymph nodes by molecular methods (Datta et
al, 1994, Schoenfeld et al, 1994; Fields et al, 1996; Noguchi et al,
1996a, 1996b). In general, the three most primitive keratins, K8,
K18 and K19, are expressed by all epithelial cells (Traweek et al,
1993). However, although K19 expression is the most epithelial
cell-specific of the primitive keratins (Traweek et al, 1993),
expression has been described in haematopoietic cells obtained
from normal volunteers (Burchill et al, 1995; Krisman et al, 1995).
Mesenchymally derived mesothelial cells are biphasic, exhibiting
both fibroblastoid and epitheloid morphologies. They may express
both keratins and vimentin (Wu et al, 1982), the intermediate fila-
ments of epithelia and mesenchyme respectively. Our studies
confirmed that K19 is expressed by the cells present in most cyto-
logically positive as well as negative effusions. For these reasons,
K19 expression is not useful for the detection of malignant
epithelial cells in effusions.
As with K19, EGP-2 is widely expressed, usually in high abun-
dance, by normal and malignant epithelial cells. However, unlike
K19, EGP-2 protein is present on the cell surface and is not
expressed by mesothelial cells. Thus, immunobead reaction with
anti-EGP-2 antibody may be utilized for selective enrichment of
carcinoma cells from malignant effusions. A similar approach has
been utilized by others for the selection of circulating colorectal or
breast carcinoma cells from peripheral blood (Hardingham et al,
1993, 1995, Eaton et al, 1997).
As a result of our preliminary experiments, we utilized
immunoselection using magnetic beads and cells coated with Ber-
EP4, a mouse monoclonal antibody against EGP-2, to selectively
enrich for carcinoma cells, followed by RT-PCR-based detection
of EGP-2 expression. Utilizing a low-EGP-2-expressing breast
carcinoma cell line, we demonstrated that the two-step assay could
detect ten tumour cells added to 107 cytologically negative effu-
sion cells. Because the selective enrichment for epithelial cells
removed most or all of the mesothelial cells, ￿false-positive￿
expression of EGP-2 by high-density mesothelial cells was
reduced or eliminated. The pathology laboratories contributing
specimens to this study refused to release them until they had been
finally signed out, frequently resulting in a delay of 2 or more days
until laboratory studies could be initiated. Although we deter-
mined that cell viability was maintained in such specimens, we
were concerned that RNA levels may decrease during refrigera-
tion. Thus, for specimens in which there was a delay longer than
48 h (19 cases), we incubated the cell pellets overnight in culture
medium at 37°C before harvesting.
We tested 110 effusions, both pleural and peritoneal, of which 18
were cytologically positive or suspicious for the presence of malig-
nant epithelial cells. EGP-2 RNA expression was detected in 17
(94%) of the positive/suspicious samples. The one ￿false-negative￿
EGP-2 515 bp
10 10
2 P 10
3 0N
Figure 3 EGP-2 RT-PCR after immunobead enrichment. No, 10, 102 and
103 breast cancer cells were spiked into 1 ´ 107 cells prepared from a
cytologically negative pleural effusion. Positive (P) and negative (N) controls
were 100 pg of RNA from MCF-7 and water blank for RT respectivelysample was from a patient with breast cancer who had received
multiagent chemotherapy recently, and whose effusion was
hypocellular. Of the 92 cytologically negative samples, EGP-2
RNA expression was detected in 11 (12%). Of these, six were from
patients with known previous or present carcinoma, whereas the
other five were from patients without known or suspected carci-
noma at the time of analysis. One subject was diagnosed with
metastatic carcinoma of unknown origin 1 month later. Details of
the outcomes of the others and our interpretations of these findings
are presented in the Results section.
The true sensitivity and specificity of our assay cannot be ascer-
tained with complete accuracy when compared with cytological
examination. If we presume that the two ￿cytologically suspicious￿
samples were really positives, the sensitivity of the molecular
assay was 17 out of 18 (94%). The true specificity of our assay is
even more difficult to determine. If we presume that all of the
cytologically negative specimens from cancer patients contained
malignant cells (including the patient who was diagnosed a month
later), as did the two cytologically ￿suspicious￿ samples, the speci-
ficity of the assay would be 19 out of 23 (83%) or better.
To the best of our knowledge, no molecular-based assay has
been utilized for the detection of malignant effusions. The molec-
ular examination we have developed appears to be a useful adjunct
to routine cytological examination of carcinomatous effusions,
especially in cases having low numbers of tumour cells or in cases
in which the cytological interpretation is difficult. Our findings
will have to be confirmed and extended in a prospective study
specifically targeting a tumour patient population.
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